Review



pam50 bioclassifier panel  (Bioclassifier LLC)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bioclassifier LLC pam50 bioclassifier panel
    Cohort characteristics
    Pam50 Bioclassifier Panel, supplied by Bioclassifier LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pam50 bioclassifier panel/product/Bioclassifier LLC
    Average 90 stars, based on 1 article reviews
    pam50 bioclassifier panel - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen"

    Article Title: A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    doi: 10.1158/1078-0432.CCR-12-0286

    Cohort characteristics
    Figure Legend Snippet: Cohort characteristics

    Techniques Used:

    Intrinsic subtype distribution by immunohistochemistry and PAM50 ( n = 348)
    Figure Legend Snippet: Intrinsic subtype distribution by immunohistochemistry and PAM50 ( n = 348)

    Techniques Used: Immunohistochemistry

    Prognosis based on PAM50 classifier for DFS (A) and OS (B).
    Figure Legend Snippet: Prognosis based on PAM50 classifier for DFS (A) and OS (B).

    Techniques Used:

    A, Kaplan–Meier curves for DFS among ER+ (local assessment) patients for tamoxifen versus placebo. B, Kaplan–Meier curves for DFS among luminal subtypes by immunohistochemistry for tamoxifen versus placebo. C, Kaplan–Meier curves for DFS among luminal subtypes by PAM50 for tamoxifen versus placebo.
    Figure Legend Snippet: A, Kaplan–Meier curves for DFS among ER+ (local assessment) patients for tamoxifen versus placebo. B, Kaplan–Meier curves for DFS among luminal subtypes by immunohistochemistry for tamoxifen versus placebo. C, Kaplan–Meier curves for DFS among luminal subtypes by PAM50 for tamoxifen versus placebo.

    Techniques Used: Immunohistochemistry



    Similar Products

    pam50 bioclassifier panel  (Bioclassifier LLC)
    90
    Bioclassifier LLC pam50 bioclassifier panel
    Cohort characteristics
    Pam50 Bioclassifier Panel, supplied by Bioclassifier LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pam50 bioclassifier panel/product/Bioclassifier LLC
    Average 90 stars, based on 1 article reviews
    pam50 bioclassifier panel - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    bioclassifier panel pam50  (Bioclassifier LLC)
    90
    Bioclassifier LLC bioclassifier panel pam50
    Cohort characteristics
    Bioclassifier Panel Pam50, supplied by Bioclassifier LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bioclassifier panel pam50/product/Bioclassifier LLC
    Average 90 stars, based on 1 article reviews
    bioclassifier panel pam50 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Cohort characteristics

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

    doi: 10.1158/1078-0432.CCR-12-0286

    Figure Lengend Snippet: Cohort characteristics

    Article Snippet: PCR primers optimized for use on FFPE materials were used to make quantitative measurements for a panel of 50 discriminatory genes (PAM50 bioclassifier panel) to segregate tumors into luminal A, luminal B, HER-2-enriched, basal-like, and normal breast–like expression profiles ( 19 ).

    Techniques:

    Intrinsic subtype distribution by immunohistochemistry and PAM50 ( n = 348)

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

    doi: 10.1158/1078-0432.CCR-12-0286

    Figure Lengend Snippet: Intrinsic subtype distribution by immunohistochemistry and PAM50 ( n = 348)

    Article Snippet: PCR primers optimized for use on FFPE materials were used to make quantitative measurements for a panel of 50 discriminatory genes (PAM50 bioclassifier panel) to segregate tumors into luminal A, luminal B, HER-2-enriched, basal-like, and normal breast–like expression profiles ( 19 ).

    Techniques: Immunohistochemistry

    Prognosis based on PAM50 classifier for DFS (A) and OS (B).

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

    doi: 10.1158/1078-0432.CCR-12-0286

    Figure Lengend Snippet: Prognosis based on PAM50 classifier for DFS (A) and OS (B).

    Article Snippet: PCR primers optimized for use on FFPE materials were used to make quantitative measurements for a panel of 50 discriminatory genes (PAM50 bioclassifier panel) to segregate tumors into luminal A, luminal B, HER-2-enriched, basal-like, and normal breast–like expression profiles ( 19 ).

    Techniques:

    A, Kaplan–Meier curves for DFS among ER+ (local assessment) patients for tamoxifen versus placebo. B, Kaplan–Meier curves for DFS among luminal subtypes by immunohistochemistry for tamoxifen versus placebo. C, Kaplan–Meier curves for DFS among luminal subtypes by PAM50 for tamoxifen versus placebo.

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

    doi: 10.1158/1078-0432.CCR-12-0286

    Figure Lengend Snippet: A, Kaplan–Meier curves for DFS among ER+ (local assessment) patients for tamoxifen versus placebo. B, Kaplan–Meier curves for DFS among luminal subtypes by immunohistochemistry for tamoxifen versus placebo. C, Kaplan–Meier curves for DFS among luminal subtypes by PAM50 for tamoxifen versus placebo.

    Article Snippet: PCR primers optimized for use on FFPE materials were used to make quantitative measurements for a panel of 50 discriminatory genes (PAM50 bioclassifier panel) to segregate tumors into luminal A, luminal B, HER-2-enriched, basal-like, and normal breast–like expression profiles ( 19 ).

    Techniques: Immunohistochemistry